Rhenium-188-HEDP in the palliative treatment of bone metastases

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 3, 2000, Pages 261-265

  Liepe, Knut ^a   Hliscs, Reiner ^a   Kropp, Joachim ^a   Grüning, Thomas ^a   Runge, Roswitha ^a   Koch, Rainer ^a   Knapp Jr , Furn F ^b   Franke, Wolf Gunter ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

Bone metastases; Pain palliation; Rhenium 188 HEDP

Indexed keywords

ETIDRONIC ACID; RHENIUM 188;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG HALF LIFE; HUMAN; PRIORITY JOURNAL;

EID: 0033861303     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497800414356     Document Type: Article

References (17)

1. Crawford D, Koslowski J, Debruyne F, et al. The use of Strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology 1994; 44: 481-485.
2. Koslowski JM, Ellis WJ, Grayhack JT: Advanced prostatic carcinoma-early versus late endocrine therapy. Clin North Am 1991; 18: 509-524.
3. Lin W, Lin C, Yeh S, Hsieh B, Tsai Z, Ting G, Yen T, Wang S, Knapp FF, Stabin M: Rhenium-188 HEDP: a new generator-product radiotherapeutic drug of potential value for treatment of bone metastases. Eur J Nucl Med 1997; 24: 590-595.
4. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1997; 37: 538-546.
5. Callahan AP, Rice D, Knapp FF Jr. Rhenium-188 for therapeutic application from an alumina based tungsten-188/Re-188 radionuclide generator. Am Commun Nucl Med 1989; 20: 3-6.
6. Maxon H, Schroder L, Washburn L, Thomas S. Rhenium-188(Sn) HEDP for treatment of osseus metastases. J Nucl Med 1998; 39: 659-663.
7. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich J, Grunewald F, Knapp FF, Biersack HJ. Dose escalation study with Re-188 HEDP in prostate cancer patients with osseous metastases. J Nucl Med 1999; Suppl 5: 218P.
8. Firusian N. Endoossale Isotopen-Therapie maligner Skeletterkrankungen. Z Krebsforschung 1978; 91: 143-156.
9. Buchali K, Correns HJ, Schnorr D, et al. 89-Strontium-therapy of skeletal metastases of prostatic carcinoma. Proceedings of the 1984 Bad Castein International Radiopharmaceutical Conference. 1984; 155-156.
10. Silberstein EB, Williams C. Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 1985; 26: 345-348.
11. Robinson R, Blake G, Preston D, McEwan A. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. RadioGraphics 1989; 9: 271-281.
12. Quility P, Kirk D, Bolger J, Dearnaly D. A comparison of the palliative effects of Strontium and external radiotherapy in metastatic prostate cancer. Radiother. Oncoi 1994; 31: 33-40.
13. Liepe K, Franke WG, Hliscs R, Kühne A, Kropp J. Rhenium-186-HEDP and Strontium-89-chloride in treatment of metastatic bone pain. Radioactive Isotopes in Clinical Medicine and Research, XXIII ed. Bergmann; Birkhäuser; Basel 1999; 79-84.
14. K. Liepe, J. Kropp, R. Hliscs, A. Kühne, W.G. Franke Radionuclide therapy in the palliative treatment of metastatic bone pain. Limouris GS (ed.) Radionuclides for Oncology. Mediterra-Publisher; Athena 1998; 185-191.
15. Porter AT, McEwan AJ, Powe R et al. Results of a randomized phase III trial to evaluate the efficiency of Strontium-89 adjuvant to local field external beam irradiation. Int J Radiation Oncology Biol Phys 1993; 25: 805-813.
16. Klerk J, Schip A, Zonnenberg B, Dijk A. Evaluation of thrombocytopenia in patients treated with Rhenium-186-HEDP. J Nucl Med 1994; 35: 1423-28.
17. Klerk J, Dieren E, Schip A, et al. Bone marrow absorbed dose of Rhenium-186-HEDP and the relationship with decreased platelets counts. J Nucl Med 1996; 37: 38-41.